# Medpace

Source: https://onco.cc/companies/medpace/  
OnCo record `medpace` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Medpace, of Cincinnati, is a mid-sized full-service contract research organisation whose physician-led model keeps medical oversight, the imaging core laboratory and central laboratories in-house, a package that biotechnology companies buy for oncology programmes. Whether in-house imaging and laboratories give cleaner oncology endpoints than outsourcing is unproven.

## Summary

Medpace, based in Cincinnati and listed as MEDP, is a mid-sized full-service contract research organisation whose clients are mostly biotechnology companies, including for oncology programmes. Its physician-led model keeps medical oversight in-house, as are its imaging core laboratory and central laboratories. OnCo links it to contract research organisations and to imaging core labs and central review. Whether keeping imaging and laboratory work in-house gives cleaner oncology endpoints than outsourcing them is the argument behind its model and the open question. The CRO technology page carries the wider picture.

## Fields

- Kind: Company
- Last checked: 2026-09-08
- Tags: supporting
- HQ: Cincinnati, OH
- Type: cro-services
- Website: https://www.medpace.com
- Ticker: MEDP

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Medpace
- Official website: https://www.medpace.com

## Connected records

- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/)
- technologies: [Contract research organisations (CROs)](https://onco.cc/technologies/contract-research-organisations/), [Imaging core labs and central review](https://onco.cc/technologies/imaging-core-labs/)
- trials: [[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications](https://onco.cc/trials/nct07432633/), [[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications](https://onco.cc/trials/nct07702292/), [177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors](https://onco.cc/trials/nct07189871/), [Azeliragon in MGMT Unmethylated Glioblastoma](https://onco.cc/trials/nct05986851/), [Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases](https://onco.cc/trials/nct06777433/), [Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC](https://onco.cc/trials/nct07197580/), [The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies](https://onco.cc/trials/nct04329728/)

---
JSON: https://onco.cc/api/v1/entities/medpace.json